Professor Mingfu Wu, Ph.D., and recent graduate Anika Nusrat, Ph.D., have identified a new cause of — and repair for — left ventricular non-compaction, also known as spongy heart disease. The new therapeutic approach, performed in utero, may prevent babies from being born with this life-threatening disease, which often causes the dire need for a heart transplant.
UHCOP faculty researcher Anirban Roy, Ph.D., has received a $300,000 grant from the Muscular Dystrophy Association to support his work focusing on Transforming Growth Factor-β–Activated Kinase 1 (TAK1), a signaling protein known to regulate inflammation, muscle growth and cell survival, in the development and progression of Duchenne muscular dystrophy (DMD).
With grant support from its national parent organization, the University of Houston College of Pharmacy chapter of the American Association of Psychiatric Pharmacists (AAPP) is launching “Operation Seizure First Aid” to strengthen seizure safety and emergency preparedness across the UH campus.
University of Houston College of Pharmacy Pharm.D. students will be presenting the highest number of research posters in Texas — and fourth highest in the nation — among their pharmacy school peers at the 2025 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exposition Dec. 7-10 in Las Vegas, Nev.
Professor Mingfu Wu, Ph.D., and recent graduate Anika Nusrat, Ph.D., have identified a new cause of — and repair for — left ventricular non-compaction, also known as spongy heart disease. The new therapeutic approach, performed in utero, may prevent babies from being born with this life-threatening disease, which often causes the dire need for a heart transplant.
UHCOP Pharm.D. candidate Tam Vu shares how family, education and hands-on community outreach shaped his path to pharmacy and why building trust and long-term relationships with patients matters most to him.
UHCOP faculty researcher Anirban Roy, Ph.D., has received a $300,000 grant from the Muscular Dystrophy Association to support his work focusing on Transforming Growth Factor-β–Activated Kinase 1 (TAK1), a signaling protein known to regulate inflammation, muscle growth and cell survival, in the development and progression of Duchenne muscular dystrophy (DMD).
Gao and team developed Nano-273, a dual-function nanodrug packaged in a tiny albumin-based particle, which both activates STING and blocks PI3Kγ—a pathway that drives Breg expansion, while albumin nanoparticles help deliver the drug directly to immune cells, reducing unwanted side effects.
Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for one of cancer’s most devastating complications.
With grant support from its national parent organization, the University of Houston College of Pharmacy chapter of the American Association of Psychiatric Pharmacists (AAPP) is launching “Operation Seizure First Aid” to strengthen seizure safety and emergency preparedness across the UH campus.